The clinical course of hepatitis B virus-associated nephropathy

Hepatitis B virus (HBV) infection is recognised as an important cause of nephrotic syndrome in endemic areas. This paper retrospectively examines the natural history and treatment of 70 patients with membranous glomerulonephritis and 1 with mesangiocapillary glomerulonephritis associated with HBV in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pediatric nephrology (Berlin, West) West), 1994-02, Vol.8 (1), p.11-14
Hauptverfasser: GILBERT, R. D, WIGGELINKHUIZEN, J
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 14
container_issue 1
container_start_page 11
container_title Pediatric nephrology (Berlin, West)
container_volume 8
creator GILBERT, R. D
WIGGELINKHUIZEN, J
description Hepatitis B virus (HBV) infection is recognised as an important cause of nephrotic syndrome in endemic areas. This paper retrospectively examines the natural history and treatment of 70 patients with membranous glomerulonephritis and 1 with mesangiocapillary glomerulonephritis associated with HBV infection. Thirty-seven patients were in complete remission by the end of the study. The average duration of proteinuria in these patients was 30 months. The cumulative probability of remission was 64% at 4 years and 84% at 10 years. Three patients were still nephrotic after more than 90 months of follow-up and 2 others had reached end-stage renal failure. Remission occurred within 6 months of clearing the antigen (HBeAg) in the majority of cases. Steroids alone were given to 10 patients and 2 received steroids and cyclophosphamide, with no beneficial effect. Three patients received interferon-alpha 2b. One cleared the HBeAg from the circulation and had a significant fall in proteinuria, but defaulted from follow-up a month after completing treatment. One had a reduction of proteinuria but remained HBeAg positive. There was no change in the condition of the third. Although the majority of children eventually enter remission, there is a significant morbidity associated with the disease. Steroids and other immunosuppressive therapy are of no benefit. Interferon therapy may be useful, but has not been adequately assessed.
doi_str_mv 10.1007/bf00868249
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00868249</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>8142208</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-96e9f3891ea4d090f9859148876a67021d2a607752265644294bde39444213d03</originalsourceid><addsrcrecordid>eNo90E1Lw0AQBuBFlFqrF-_CHjwJ0dmP7MdJbLEqFLxU6C1sN7tkpU3CbiL03xtp7GkG3oeBeRG6JfBIAOTT1gMooSjXZ2hKOKMZ0WpzjqagGcmAk80lukrpGwaWKzFBE0U4paCm6HldOWx3oQ7W7LBt-pgcbjyuXGu60IWE5_gnxD5lJqXGBtO5EteurWIzgOpwjS682SV3M84Z-lq-rhfv2erz7WPxssosk7LLtHDaM6WJM7wEDV6rXBOulBRGSKCkpEaAlDmlIhecU823pWOaDythJbAZejjetbFJKTpftDHsTTwUBIq_Eor58r-EAd8dcdtv96480fHrIb8fc5OGt300tQ3pxJhmoCllvwnkYYQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>The clinical course of hepatitis B virus-associated nephropathy</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>GILBERT, R. D ; WIGGELINKHUIZEN, J</creator><creatorcontrib>GILBERT, R. D ; WIGGELINKHUIZEN, J</creatorcontrib><description>Hepatitis B virus (HBV) infection is recognised as an important cause of nephrotic syndrome in endemic areas. This paper retrospectively examines the natural history and treatment of 70 patients with membranous glomerulonephritis and 1 with mesangiocapillary glomerulonephritis associated with HBV infection. Thirty-seven patients were in complete remission by the end of the study. The average duration of proteinuria in these patients was 30 months. The cumulative probability of remission was 64% at 4 years and 84% at 10 years. Three patients were still nephrotic after more than 90 months of follow-up and 2 others had reached end-stage renal failure. Remission occurred within 6 months of clearing the antigen (HBeAg) in the majority of cases. Steroids alone were given to 10 patients and 2 received steroids and cyclophosphamide, with no beneficial effect. Three patients received interferon-alpha 2b. One cleared the HBeAg from the circulation and had a significant fall in proteinuria, but defaulted from follow-up a month after completing treatment. One had a reduction of proteinuria but remained HBeAg positive. There was no change in the condition of the third. Although the majority of children eventually enter remission, there is a significant morbidity associated with the disease. Steroids and other immunosuppressive therapy are of no benefit. Interferon therapy may be useful, but has not been adequately assessed.</description><identifier>ISSN: 0931-041X</identifier><identifier>EISSN: 1432-198X</identifier><identifier>DOI: 10.1007/bf00868249</identifier><identifier>PMID: 8142208</identifier><identifier>CODEN: PENED3</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adolescent ; Biological and medical sciences ; Child ; Child, Preschool ; Creatinine - urine ; Cyclophosphamide - therapeutic use ; Female ; Follow-Up Studies ; Glomerulonephritis, Membranoproliferative - etiology ; Glomerulonephritis, Membranoproliferative - therapy ; Glomerulonephritis, Membranous - etiology ; Glomerulonephritis, Membranous - therapy ; Glucocorticoids - therapeutic use ; Hepatitis B - complications ; Hepatitis B - immunology ; Hepatitis B e Antigens - immunology ; Hepatitis B Surface Antigens - immunology ; Humans ; Infant ; Interferon alpha-2 ; Interferon-alpha - therapeutic use ; Kidneys ; Male ; Medical sciences ; Nephrology. Urinary tract diseases ; Proteinuria - therapy ; Recombinant Proteins ; Retrospective Studies ; Urinary system involvement in other diseases. Miscellaneous</subject><ispartof>Pediatric nephrology (Berlin, West), 1994-02, Vol.8 (1), p.11-14</ispartof><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-96e9f3891ea4d090f9859148876a67021d2a607752265644294bde39444213d03</citedby><cites>FETCH-LOGICAL-c377t-96e9f3891ea4d090f9859148876a67021d2a607752265644294bde39444213d03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3930922$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8142208$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GILBERT, R. D</creatorcontrib><creatorcontrib>WIGGELINKHUIZEN, J</creatorcontrib><title>The clinical course of hepatitis B virus-associated nephropathy</title><title>Pediatric nephrology (Berlin, West)</title><addtitle>Pediatr Nephrol</addtitle><description>Hepatitis B virus (HBV) infection is recognised as an important cause of nephrotic syndrome in endemic areas. This paper retrospectively examines the natural history and treatment of 70 patients with membranous glomerulonephritis and 1 with mesangiocapillary glomerulonephritis associated with HBV infection. Thirty-seven patients were in complete remission by the end of the study. The average duration of proteinuria in these patients was 30 months. The cumulative probability of remission was 64% at 4 years and 84% at 10 years. Three patients were still nephrotic after more than 90 months of follow-up and 2 others had reached end-stage renal failure. Remission occurred within 6 months of clearing the antigen (HBeAg) in the majority of cases. Steroids alone were given to 10 patients and 2 received steroids and cyclophosphamide, with no beneficial effect. Three patients received interferon-alpha 2b. One cleared the HBeAg from the circulation and had a significant fall in proteinuria, but defaulted from follow-up a month after completing treatment. One had a reduction of proteinuria but remained HBeAg positive. There was no change in the condition of the third. Although the majority of children eventually enter remission, there is a significant morbidity associated with the disease. Steroids and other immunosuppressive therapy are of no benefit. Interferon therapy may be useful, but has not been adequately assessed.</description><subject>Adolescent</subject><subject>Biological and medical sciences</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Creatinine - urine</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Glomerulonephritis, Membranoproliferative - etiology</subject><subject>Glomerulonephritis, Membranoproliferative - therapy</subject><subject>Glomerulonephritis, Membranous - etiology</subject><subject>Glomerulonephritis, Membranous - therapy</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Hepatitis B - complications</subject><subject>Hepatitis B - immunology</subject><subject>Hepatitis B e Antigens - immunology</subject><subject>Hepatitis B Surface Antigens - immunology</subject><subject>Humans</subject><subject>Infant</subject><subject>Interferon alpha-2</subject><subject>Interferon-alpha - therapeutic use</subject><subject>Kidneys</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Proteinuria - therapy</subject><subject>Recombinant Proteins</subject><subject>Retrospective Studies</subject><subject>Urinary system involvement in other diseases. Miscellaneous</subject><issn>0931-041X</issn><issn>1432-198X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo90E1Lw0AQBuBFlFqrF-_CHjwJ0dmP7MdJbLEqFLxU6C1sN7tkpU3CbiL03xtp7GkG3oeBeRG6JfBIAOTT1gMooSjXZ2hKOKMZ0WpzjqagGcmAk80lukrpGwaWKzFBE0U4paCm6HldOWx3oQ7W7LBt-pgcbjyuXGu60IWE5_gnxD5lJqXGBtO5EteurWIzgOpwjS682SV3M84Z-lq-rhfv2erz7WPxssosk7LLtHDaM6WJM7wEDV6rXBOulBRGSKCkpEaAlDmlIhecU823pWOaDythJbAZejjetbFJKTpftDHsTTwUBIq_Eor58r-EAd8dcdtv96480fHrIb8fc5OGt300tQ3pxJhmoCllvwnkYYQ</recordid><startdate>19940201</startdate><enddate>19940201</enddate><creator>GILBERT, R. D</creator><creator>WIGGELINKHUIZEN, J</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19940201</creationdate><title>The clinical course of hepatitis B virus-associated nephropathy</title><author>GILBERT, R. D ; WIGGELINKHUIZEN, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-96e9f3891ea4d090f9859148876a67021d2a607752265644294bde39444213d03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Adolescent</topic><topic>Biological and medical sciences</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Creatinine - urine</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Glomerulonephritis, Membranoproliferative - etiology</topic><topic>Glomerulonephritis, Membranoproliferative - therapy</topic><topic>Glomerulonephritis, Membranous - etiology</topic><topic>Glomerulonephritis, Membranous - therapy</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Hepatitis B - complications</topic><topic>Hepatitis B - immunology</topic><topic>Hepatitis B e Antigens - immunology</topic><topic>Hepatitis B Surface Antigens - immunology</topic><topic>Humans</topic><topic>Infant</topic><topic>Interferon alpha-2</topic><topic>Interferon-alpha - therapeutic use</topic><topic>Kidneys</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Proteinuria - therapy</topic><topic>Recombinant Proteins</topic><topic>Retrospective Studies</topic><topic>Urinary system involvement in other diseases. Miscellaneous</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GILBERT, R. D</creatorcontrib><creatorcontrib>WIGGELINKHUIZEN, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Pediatric nephrology (Berlin, West)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GILBERT, R. D</au><au>WIGGELINKHUIZEN, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The clinical course of hepatitis B virus-associated nephropathy</atitle><jtitle>Pediatric nephrology (Berlin, West)</jtitle><addtitle>Pediatr Nephrol</addtitle><date>1994-02-01</date><risdate>1994</risdate><volume>8</volume><issue>1</issue><spage>11</spage><epage>14</epage><pages>11-14</pages><issn>0931-041X</issn><eissn>1432-198X</eissn><coden>PENED3</coden><abstract>Hepatitis B virus (HBV) infection is recognised as an important cause of nephrotic syndrome in endemic areas. This paper retrospectively examines the natural history and treatment of 70 patients with membranous glomerulonephritis and 1 with mesangiocapillary glomerulonephritis associated with HBV infection. Thirty-seven patients were in complete remission by the end of the study. The average duration of proteinuria in these patients was 30 months. The cumulative probability of remission was 64% at 4 years and 84% at 10 years. Three patients were still nephrotic after more than 90 months of follow-up and 2 others had reached end-stage renal failure. Remission occurred within 6 months of clearing the antigen (HBeAg) in the majority of cases. Steroids alone were given to 10 patients and 2 received steroids and cyclophosphamide, with no beneficial effect. Three patients received interferon-alpha 2b. One cleared the HBeAg from the circulation and had a significant fall in proteinuria, but defaulted from follow-up a month after completing treatment. One had a reduction of proteinuria but remained HBeAg positive. There was no change in the condition of the third. Although the majority of children eventually enter remission, there is a significant morbidity associated with the disease. Steroids and other immunosuppressive therapy are of no benefit. Interferon therapy may be useful, but has not been adequately assessed.</abstract><cop>Heidelberg</cop><pub>Springer</pub><pmid>8142208</pmid><doi>10.1007/bf00868249</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0931-041X
ispartof Pediatric nephrology (Berlin, West), 1994-02, Vol.8 (1), p.11-14
issn 0931-041X
1432-198X
language eng
recordid cdi_crossref_primary_10_1007_BF00868249
source MEDLINE; SpringerLink Journals - AutoHoldings
subjects Adolescent
Biological and medical sciences
Child
Child, Preschool
Creatinine - urine
Cyclophosphamide - therapeutic use
Female
Follow-Up Studies
Glomerulonephritis, Membranoproliferative - etiology
Glomerulonephritis, Membranoproliferative - therapy
Glomerulonephritis, Membranous - etiology
Glomerulonephritis, Membranous - therapy
Glucocorticoids - therapeutic use
Hepatitis B - complications
Hepatitis B - immunology
Hepatitis B e Antigens - immunology
Hepatitis B Surface Antigens - immunology
Humans
Infant
Interferon alpha-2
Interferon-alpha - therapeutic use
Kidneys
Male
Medical sciences
Nephrology. Urinary tract diseases
Proteinuria - therapy
Recombinant Proteins
Retrospective Studies
Urinary system involvement in other diseases. Miscellaneous
title The clinical course of hepatitis B virus-associated nephropathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T03%3A30%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20clinical%20course%20of%20hepatitis%20B%20virus-associated%20nephropathy&rft.jtitle=Pediatric%20nephrology%20(Berlin,%20West)&rft.au=GILBERT,%20R.%20D&rft.date=1994-02-01&rft.volume=8&rft.issue=1&rft.spage=11&rft.epage=14&rft.pages=11-14&rft.issn=0931-041X&rft.eissn=1432-198X&rft.coden=PENED3&rft_id=info:doi/10.1007/bf00868249&rft_dat=%3Cpubmed_cross%3E8142208%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/8142208&rfr_iscdi=true